; (B) fails to meet the requirements described in subsection (c); or (C) does not complete a postmarket study required by the Food and Drug Administration during the term of the contract; (2) the annual international and private insurance market revenues with respect to an antimicrobial drug (not counting any subscription revenues from any source pursuant to a contract under this section or other international or private entities) exceed 5 times the average annual amount of the subscription contract paid by the Secretary as certified by the sponsor annually